Senescent cells stop dividing but remain active. They can support wound healing, while persistent accumulation is associated with inflammation and age-related disease.

The NIH-supported SenNet consortium is mapping these cells across tissues and ages. Its framework favours combinations of molecular traits over a single universal test.

The implication is important but measured: better identification may enable more targeted senolytic interventions. It does not yet demonstrate a life-extending therapy.